EA
BPMC

Emerald Advisers’s Blueprint Medicines BPMC Stock Holding History

Emerald Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-401,644
Closed -$35.5M – 251
2025
Q1 		$35.5M Sell
401,644
-15,222
-4% -$1.48M 1.6% 14
2024
Q4 		$36.4M Buy
416,866
+41,000
+11% +$3.76M 1.41% 16
2024
Q3 		$34.8M Buy
375,866
+34,666
+10% +$3.44M 1.34% 19
2024
Q2 		$36.8M Sell
341,200
-61,710
-15% -$6.18M 1.54% 10
2024
Q1 		$38.2M Sell
402,910
-63,516
-14% -$5.45M 1.54% 11
2023
Q4 		$43M Sell
466,426
-140,611
-23% -$9.11M 1.84% 8
2023
Q3 		$30.5M Buy
607,037
+110,984
+22% +$5.93M 1.48% 12
2023
Q2 		$31.4M Buy
496,053
+57,804
+13% +$3.14M 1.37% 14
2023
Q1 		$19.7M Buy
438,249
+47,093
+12% +$2.12M 0.95% 40
2022
Q4 		$17.1M Buy
391,156
+72,582
+23% +$3.48M 0.83% 53
2022
Q3 		$21M Buy
+318,574
New +$20.5M 1.08% 31
2022
Q1 		– Sell
-169,659
Closed -$18.2M – 268
2021
Q4 		$18.2M Sell
169,659
-63,849
-27% -$6.68M 0.67% 64
2021
Q3 		$24M Buy
233,508
+7,173
+3% +$668K 0.87% 47
2021
Q2 		$19.9M Sell
226,335
-33,799
-13% -$3.1M 0.73% 58
2021
Q1 		$25.3M Sell
260,134
-37,771
-13% -$3.77M 0.91% 39
2020
Q4 		$33.4M Sell
297,905
-82,684
-22% -$8.71M 1.11% 23
2020
Q3 		$35.3M Sell
380,589
-14,896
-4% -$1.15M 1.45% 15
2020
Q2 		$30.8M Sell
395,485
-20,681
-5% -$1.4M 1.34% 21
2020
Q1 		$24.3M Buy
+416,166
New +$26.8M 1.41% 18

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emerald Advisers's BPMC Position: Q2 2025 in Review

Emerald Advisers sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 401,644 shares — an estimated $35.5M sold.

Emerald Advisers first reported a position in BPMC in Q1 2020 and held it in 19 quarters. The position peaked at $43M in Q4 2023. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Emerald Advisers reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Emerald Advisers sold 401,644 Blueprint Medicines shares in Q2 2025, an estimated $35.5M.
  • Emerald Advisers first reported a position in Blueprint Medicines in Q1 2020 and held it in 19 quarters.
  • Emerald Advisers's Blueprint Medicines position peaked at $43M in Q4 2023.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Emerald Advisers's 13F filing for Q2 2025, filed 4 Aug 2025.